Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
Trial details
- Registry ID
- NCT06463028
- Drugs studied
- Paclitaxel, Sapanisertib, Serabelisib
TrialRedline tracks 2 clinical trials sponsored by Faeth Therapeutics: 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial CancerNCT06463028 | Paclitaxel, Sapanisertib, Serabelisib | Recruiting | 2028-09Estimated |
| A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung CancerNCT05275673 | sapanisertib | Terminated | 2023-01-24Actual |
Names as written in the registry records.